Cost savings with nefazodone in treating depression

Robert E Hales, Donald M. Hilty, Gregory H. Brunson

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Pharmacoeconomic analysis of antidepressant therapy is an important tool for ensuring the most cost-cognizant approach to treat a particular mental disorder. As the number of effective antidepressant compounds continues to grow, the drug selection process must consider not only the cost of the drug itself, but also costs associated with treatment failure and management of untoward and unexpected side effects. In economic studies conducted in North America and England using a decision analysis model and a direct annual cost model, nefazodone has been shown to have an impact on costs associated with depression when compared with imipramine and fluoxetine. Nefazodone also can reduce depression-related anxiety and agitation symptoms early in treatment, and, because it improves subjective and objective sleep measures, use of concomitant anxiolytics or sedative-hypnotics with nefazodone has been shown to be less frequent and less costly than with selective serotonin reuptake inhibitors.

Original languageEnglish (US)
Pages (from-to)48-51
Number of pages4
JournalJournal of Clinical Psychiatry
Volume63
Issue numberSUPPL. 1
StatePublished - 2002

Fingerprint

Cost Savings
Depression
Costs and Cost Analysis
Antidepressive Agents
Pharmaceutical Economics
Drug Costs
Decision Support Techniques
Imipramine
Fluoxetine
Anti-Anxiety Agents
Serotonin Uptake Inhibitors
North America
Treatment Failure
Hypnotics and Sedatives
Mental Disorders
England
Sleep
Anxiety
Economics
nefazodone

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Hales, R. E., Hilty, D. M., & Brunson, G. H. (2002). Cost savings with nefazodone in treating depression. Journal of Clinical Psychiatry, 63(SUPPL. 1), 48-51.

Cost savings with nefazodone in treating depression. / Hales, Robert E; Hilty, Donald M.; Brunson, Gregory H.

In: Journal of Clinical Psychiatry, Vol. 63, No. SUPPL. 1, 2002, p. 48-51.

Research output: Contribution to journalArticle

Hales, RE, Hilty, DM & Brunson, GH 2002, 'Cost savings with nefazodone in treating depression', Journal of Clinical Psychiatry, vol. 63, no. SUPPL. 1, pp. 48-51.
Hales, Robert E ; Hilty, Donald M. ; Brunson, Gregory H. / Cost savings with nefazodone in treating depression. In: Journal of Clinical Psychiatry. 2002 ; Vol. 63, No. SUPPL. 1. pp. 48-51.
@article{452ea9de7bac43c0ba08771bae532bbe,
title = "Cost savings with nefazodone in treating depression",
abstract = "Pharmacoeconomic analysis of antidepressant therapy is an important tool for ensuring the most cost-cognizant approach to treat a particular mental disorder. As the number of effective antidepressant compounds continues to grow, the drug selection process must consider not only the cost of the drug itself, but also costs associated with treatment failure and management of untoward and unexpected side effects. In economic studies conducted in North America and England using a decision analysis model and a direct annual cost model, nefazodone has been shown to have an impact on costs associated with depression when compared with imipramine and fluoxetine. Nefazodone also can reduce depression-related anxiety and agitation symptoms early in treatment, and, because it improves subjective and objective sleep measures, use of concomitant anxiolytics or sedative-hypnotics with nefazodone has been shown to be less frequent and less costly than with selective serotonin reuptake inhibitors.",
author = "Hales, {Robert E} and Hilty, {Donald M.} and Brunson, {Gregory H.}",
year = "2002",
language = "English (US)",
volume = "63",
pages = "48--51",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Cost savings with nefazodone in treating depression

AU - Hales, Robert E

AU - Hilty, Donald M.

AU - Brunson, Gregory H.

PY - 2002

Y1 - 2002

N2 - Pharmacoeconomic analysis of antidepressant therapy is an important tool for ensuring the most cost-cognizant approach to treat a particular mental disorder. As the number of effective antidepressant compounds continues to grow, the drug selection process must consider not only the cost of the drug itself, but also costs associated with treatment failure and management of untoward and unexpected side effects. In economic studies conducted in North America and England using a decision analysis model and a direct annual cost model, nefazodone has been shown to have an impact on costs associated with depression when compared with imipramine and fluoxetine. Nefazodone also can reduce depression-related anxiety and agitation symptoms early in treatment, and, because it improves subjective and objective sleep measures, use of concomitant anxiolytics or sedative-hypnotics with nefazodone has been shown to be less frequent and less costly than with selective serotonin reuptake inhibitors.

AB - Pharmacoeconomic analysis of antidepressant therapy is an important tool for ensuring the most cost-cognizant approach to treat a particular mental disorder. As the number of effective antidepressant compounds continues to grow, the drug selection process must consider not only the cost of the drug itself, but also costs associated with treatment failure and management of untoward and unexpected side effects. In economic studies conducted in North America and England using a decision analysis model and a direct annual cost model, nefazodone has been shown to have an impact on costs associated with depression when compared with imipramine and fluoxetine. Nefazodone also can reduce depression-related anxiety and agitation symptoms early in treatment, and, because it improves subjective and objective sleep measures, use of concomitant anxiolytics or sedative-hypnotics with nefazodone has been shown to be less frequent and less costly than with selective serotonin reuptake inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0036194022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036194022&partnerID=8YFLogxK

M3 - Article

C2 - 11890565

AN - SCOPUS:0036194022

VL - 63

SP - 48

EP - 51

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - SUPPL. 1

ER -